Antiviral Drug Ensitrelvir:
A recent study published in The New England Journal of Medicine reported that the antiviral drug Ensitrelvir significantly reduced symptomatic COVID-19 infections among exposed household contacts.
- Ensitrelvir is an oral antiviral drug that inhibits the SARS-CoV-2 main protease (3C-like protease/Mpro), an enzyme essential for viral replication.
- By blocking this protease, the drug prevents the coronavirus from processing viral proteins required for multiplication inside human cells.
- Aim:
- To treat mild-to-moderate COVID-19 infections and reduce viral transmission after exposure.
- To provide a safer and longer-lasting oral antiviral option without requiring booster drugs like ritonavir.
- Key Features:
- Protease Inhibitor Mechanism: Targets the SARS-CoV-2 main protease (Mpro), preventing viral replication.
- Oral Antiviral Drug: Can be administered orally, making it suitable for outpatient and household use.
- Broad Variant Activity: Showed effectiveness against multiple SARS-CoV-2 variants, including Omicron.
- Better Safety Profile: Remains longer in the bloodstream without requiring ritonavir and avoids the bitter aftertaste associated with some COVID antivirals.
